Becton Dickinson/$BDX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Becton Dickinson

Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.

Ticker

$BDX
Sector

Primary listing

NYSE

Employees

74,000

Becton Dickinson Metrics

BasicAdvanced
$56B
35.45
$5.47
0.28
$4.16
2.15%

What the Analysts think about Becton Dickinson

Analyst ratings (Buy, Hold, Sell) for Becton Dickinson stock.

Bulls say / Bears say

After reporting Q3 2025 adjusted EPS of $3.68—beating estimates by $0.28—and revenue of $5.51 billion, BD raised its full-year adjusted EPS guidance to $14.30–$14.45, up from $14.06–$14.34, citing strong demand for its drug-delivery devices (Reuters).
BD agreed to a $17.5 billion Reverse Morris Trust transaction to merge its Biosciences & Diagnostic Solutions division with Waters Corporation, a move projected to double Waters’ total addressable market to $40 billion and unlock $345 million in annual cost savings by 2030 (Reuters).
The company plans to invest $2.5 billion in U.S. manufacturing capacity over the next five years, strengthening its domestic production footprint and enhancing resilience of its supply chain (Reuters).
Becton Dickinson lowered its full-year adjusted EPS forecast to $14.06–$14.34, reflecting a ~$0.25 per share headwind from proposed U.S. tariffs, which sent its shares down about 5% in pre-market trading on May 1, 2025 (Reuters).
Global cuts in research funding, notably U.S. government grants, have depressed sales of BD’s research instruments, triggering a more than 15% one-day stock plunge—the worst since 1999—when the company disclosed these headwinds on May 1, 2025 (MarketWatch).
Second-quarter 2025 revenues of $5.27 billion missed the Wall Street estimate of $5.35 billion, reflecting softer top-line momentum and contributing to a 5% share decline on May 1, 2025 (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.

Becton Dickinson Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Becton Dickinson Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BDX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs
Buy Becton Dickinson stock | $BDX Share Price | Lightyear